Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

BACKGROUND: Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with chemotherapy plus anti-EGFR in previously treated patients with BRAF V600E-mutated (mut) metastatic colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., Cremolini, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271503/
https://www.ncbi.nlm.nih.gov/pubmed/35696748
http://dx.doi.org/10.1016/j.esmoop.2022.100506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271503/
https://www.ncbi.nlm.nih.gov/pubmed/35696748
http://dx.doi.org/10.1016/j.esmoop.2022.100506

Ejemplares similares